Karyopharm Therapeutics Inc. (NASDAQ: KPTI)
$0.99
-0.0129 ( -1.29% ) 901.4K
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Market Data
Open
$0.99
Previous close
$1.00
Volume
901.4K
Market cap
$122.12M
Day range
$0.96 - $1.04
52 week range
$0.62 - $1.95
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 12 | Dec 12, 2023 |
8-k | 8K-related | 12 | Dec 08, 2023 |
4 | Insider transactions | 1 | Dec 05, 2023 |
4 | Insider transactions | 1 | Nov 07, 2023 |
8-k | 8K-related | 14 | Nov 02, 2023 |
10-q | Quarterly Reports | 63 | Nov 02, 2023 |
4 | Insider transactions | 1 | Oct 05, 2023 |
4 | Insider transactions | 1 | Sep 12, 2023 |
4 | Insider transactions | 1 | Sep 06, 2023 |
4 | Insider transactions | 1 | Sep 05, 2023 |